With risk assessments being required for more and more pharma/biopharma decisions, health authorities are spending more time reading through them and asking questions about a firm’s quality risk management (QRM) system, the methods used in conducting a risk assessment, and the risk assessment itself. This presentation identifies frequently seen weaknesses in a QRM program and specific areas to examine in preparation for an audit or inspection.